Monday, August 7, 2017
QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.
Congresswoman Rosa DeLauro (CT-03) has announced the Prescription Drug and Medical Device Review Board Act, new legislation that would create a national review board to stop pharmaceutical corporations from charging consumers excessive prices. According to a recent report released by IMS Health Holdings, annual spending on prescription medications has skyrocketed in the U.S. in recent years, and is projected to increase by 22% over the next five years, climbing to as high as $400 billion by 2020.
ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced senior appointments to its clinical research, medical imaging and commercialization and outcomes services. Dr. Andrew Garrett has been appointed executive vice president, Scientific Operations, Dr. Paul McCracken has joined ICON as vice president, Medical Imaging and Jim Carroll has been appointed vice president, Real World Evidence (RWE).
Quintiles IMS Holdings has successfully completed its merger of equals transaction between IMS Health Holdings and Quintiles Transnational Holdings. The merger of IMS Health, a global information and technology services company, and Quintiles, a provider of product development and integrated healthcare services, creates an information and tech-enabled healthcare service provider with global scale and reach, and a full suite of end-to-end clinical and commercial offerings.
The IMS Institute for Healthcare Informatics has announced the launch of a new branch focused on supporting improved health outcomes across Asia. Based in Singapore, the team will forge relationships in the public and private sectors and apply analytics-driven approaches, based on Real-World Evidence, for disease modeling and insights—providing regional markets with much-needed tools to make better and more cost-effective healthcare policy decisions.
Pharmaceutical Product Development (PPD) has agreed to buy Evidera, a Maryland-based company that provides evidence-based solutions for the healthcare industry, as demand rises for research that shows the effectiveness and value of new medicines in real-world settings.
After indicating it was gearing up for an imminent initial public offering, CRO inVentiv Health last week went in a different direction. Instead, the equity group Advent International Corp. has purchased a 50% stake in the company, making Advent a co-owner of the CRO with Thomas H. Lee Partners, which bought inVentiv in 2010 for approximately $1.1 billion.
IMS Health has acquired Privacy Analytics, a provider of technology solutions for de-identifying and anonymizing healthcare information, to extend its Real-World Evidence (RWE) capabilities. Affirming IMS Health’s long-standing practices for safeguarding patient privacy, the acquisition advances the company’s ability to help life sciences clients drive R&D and commercial performance and demonstrate treatment value in real-world settings. It also reinforces IMS Health’s role as a partner of choice for health systems, payers, providers and researchers as they seek new insights from healthcare data—with strong support for responsible privacy management.